{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:12:43Z","timestamp":1791313963593,"version":"4.3.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.pharep.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T17:48:37Z","timestamp":1411753717000},"page":"353-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity"],"prefix":"10.1007","volume":"67","author":[{"given":"Jaros\u0142aw","family":"Sobi\u015b","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rykaczewska-Czerwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"\u015awi\u0119tochowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Gorczyca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00023210-200418002-00002","article-title":"Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life","volume":"18","author":"Lambert","year":"2004","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.007_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.09.007_bib0015","first-page":"104","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Clark","year":"2004","journal-title":"Diabetes Care"},{"issue":"2\/3","key":"10.1016\/j.pharep.2014.09.007_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharep.2014.09.007_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-244X-8-95","article-title":"The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)","volume":"8","author":"Hanssens","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharep.2014.09.007_bib0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pharep.2014.09.007_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"40","key":"10.1016\/j.pharep.2014.09.007_bib0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pnpbp.2012.10.010","article-title":"Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs","volume":"10","author":"Wang","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.007_bib0050","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/schbul\/sbl037","article-title":"A case series: evaluation of the metabolic safety of aripiprazole","volume":"33","author":"De Hert","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharep.2014.09.007_bib0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharep.2014.09.007_bib0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0447.2008.01232.x","article-title":"A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole","volume":"118","author":"Schorr","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharep.2014.09.007_bib0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/nedt.1.2.171.61048","article-title":"Increased serum interleukin-1\u03b2 and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication","volume":"1","author":"Schmitt","year":"2005","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pharep.2014.09.007_bib0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4236\/abb.2012.324072","article-title":"In vivo immunomodulatory effects of antipsychotics on inflammatory mediators: a review","volume":"3","author":"Tourjman","year":"2012","journal-title":"Adv Biosci Biotechnol"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.007_bib0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharep.2014.09.007_bib0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2010.05.060","article-title":"Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state","volume":"1350","author":"Victoriano","year":"2010","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.007_bib0090","doi-asserted-by":"crossref","first-page":"59012","DOI":"10.1371\/journal.pone.0059012","article-title":"Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells","volume":"8","author":"Contreras-Shannon","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.007_bib0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm.2627","article-title":"The cellular and signaling networks linking the immune system and metabolism in disease","volume":"18","author":"Osborn","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pharep.2014.09.007_bib0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.pharep.2014.09.007_bib0110","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharep.2014.09.007_bib0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"202","author":"Langrish","year":"2004","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.007_bib0120","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI25308","article-title":"Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis","volume":"116","author":"Chen","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharep.2014.09.007_bib0125","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.007_bib0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ijo.2008.216","article-title":"Increased activity of interleukin-23\/interleukin-17 proinflammatory axis in obese women","volume":"33","author":"Sumarac-Dumanovic","year":"2009","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.007_bib0135","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1152\/japplphysiol.00164.2004","article-title":"The anti-inflammatory effect of exercise","volume":"98","author":"Petersen","year":"2005","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharep.2014.09.007_bib0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.007_bib0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/EJE-07-0721","article-title":"Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study","volume":"158","author":"Madsen","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.007_bib0155","first-page":"58","article-title":"Little evidence of systemic and adipose tissue inflammation in overweight individuals(\u2020)","volume":"19","author":"Tam","year":"2012","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.007_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharep.2014.09.007_bib0165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2012.10.041","article-title":"C-reactive protein is elevated in schizophrenia","volume":"143","author":"Dickerson","year":"2013","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.pharep.2014.09.007_bib0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.09.007_bib0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2012.06.040","article-title":"Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein","volume":"140","author":"Dieset","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharep.2014.09.007_bib0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.007_bib0185","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.pharep.2014.09.007_bib0190","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study","volume":"70","author":"Smith","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharep.2014.09.007_bib0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","article-title":"Interleukin-10: new perspectives on an old cytokine","volume":"226","author":"Mosser","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharep.2014.09.007_bib0200","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/dc08-1161","article-title":"Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II Study","volume":"32","author":"Herder","year":"2009","journal-title":"Diabetes Care"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.09.007_bib0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2012.12.023","article-title":"Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder","volume":"145","author":"Hope","year":"2013","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.007_bib0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cytogfr.2010.09.002","article-title":"Biology of interleukin-10","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.007_bib0215","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2337\/diabetes.51.4.1088","article-title":"Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study","volume":"51","author":"van Exel","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pharep.2014.09.007_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10254-003-0012-2","article-title":"IL-6 signal transduction and its physiological roles: the signal orchestration model","volume":"149","author":"Kamimura","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.pharep.2014.09.007_bib0225","first-page":"5203","article-title":"Interleukins 17 and 23 and resistin levels among obese diabetic Egyptian female patients","volume":"8","author":"Kandeel","year":"2012","journal-title":"J Appl Sci Res"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.007_bib0230","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharep.2014.09.007_bib0235","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/intimm\/dxh247","article-title":"IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages","volume":"17","author":"Schuetze","year":"2005","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.007_bib0240","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1084\/jem.20071450","article-title":"Differential regulation of interleukin-12 and interleukin-23 production in human dendritic cells","volume":"205","author":"Gerosa","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharep.2014.09.007_bib0245","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","article-title":"Hyperlipidemia following treatment with antipsychotic medications","volume":"163","author":"Olfson","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.pharep.2014.09.007_bib0250","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4088\/JCP.v68n1006","article-title":"Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole vs olanzapine or placebo","volume":"68","author":"L\u2019Italien","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:44Z","timestamp":1752611744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.09.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1734114014002916"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.09.007","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}